Cardiac Marker Testing Devices Market will generate new growth opportunities 2021-2028 | Elekta, Eckert & Zieglar BEBIG, and Varian Medical Systems, Inc.

Cardiac markers, also called biomarkers, are analyzes measured to assess heart function. They are very important in the pre-diagnosis or prediction of certain disease. While they are mostly talked about in the context of coronary heart disease, some other conditions may also result to an increased elevation of cardiac marker level.

A cardiac marker usually involves either a blood test (e.g., beta-blocker) or a biochemical procedure (e.g., myoglobin). Due to the fact that myoglobin is composed of amino acids, its absorption by the body is normal. Myoglobin, together with triglycerides, is the major component of the red blood cells. The amount of myoglobin determines the intensity of a heart condition. Accordingly, it can also provide information on the extent of peripheral vasoconstriction or widening of peripheral blood vessels, which can facilitate the occurrence of cardiogenic shock.

To Get more Business Statergies Request for Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/1039

Recent Developments:

Major players operating in the global cardiac marker testing devices market are focused on adopting M&A strategies to expand their product portfolio. For instance, in 2016, Abbott and Alere Inc. announced a definitive agreement for Abbott to acquire Alere to expand its point-of-care testing business.

Major players operating in the global cardiac marker testing devices market are focused on launching new products to expand their product portfolio. For instance, in September 2019, Sanskritech Smart Solutions Pvt Ltd launched ‘Swayam AHM’, a self-monitoring health diagnostic Point of Care Testing (POCT) system.

Global Cardiac Marker Testing Devices Market: Drivers

High prevalence of coronary artery disease is expected to propel growth of the global cardiac marker testing devices market over the forecast period. For instance, according to ‘Heart disease and stroke statistics—2019 update’, a report from the American Heart Association, published in 2019, CAD accounted for 365,914 deaths in the U.S. in 2017

Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to The United Nations Economic and Social Commission for Asia and the Pacific, over a third of the population in Asia Pacific is expected to be 60 years or older by 2050.

Market Trends: 

North America is expected to witness significant demand for cardiac marker testing devices with high prevalence of lifestyle diseases and high substance and alcohol abuse. For instance, according to the 2018 National Survey on Drug Use and Health, in the U.S., around 164.8 million people aged 12 or older in the U.S. were past month substance users that included tobacco, alcohol, or illicit drugs. Major acquisitions are expected to drive growth of the cardiac marker testing devices market

Major players operating in the global cardiac marker testing devices market are focused on launching new products to expand their product portfolio. For instance, in May 2016, Royal Philips launched the Minicare I-20 system, a handheld blood test for rapid diagnosis of heart attack.

To Get Research PDF Brochure Here @ https://www.coherentmarketinsights.com/insight/request-pdf/1039

Global Cardiac Marker Testing Devices Market: Competitive Landscape

Major players operating in the global cardiac marker testing devices market are Abbott Laboratories, Bio-Rad Laboratories, Inc., bioMerieux SA, Becton, Dickinson and Company, Danaher Corporation, Enzo Biochem Inc., F. Hoffmann-La Roche Ltd., Helomics Corp., LSI Medience Corporation, Ortho Clinical Diagnostics, Randox Laboratories Ltd., and Siemens Medical Solutions USA, Inc.

Global Cardiac Marker Testing Devices Market: Key Developments

Major players operating in the global cardiac marker testing devices market are focused on adopting M&A strategies to expand their product portfolio. For instance, in 2017, Quidel Corporation entered into definitive agreements to acquire the Triage MeterPro cardiovascular (CV) and toxicology assets and the B-type Naturietic Peptide assay business run on Beckman Coulter analyzers from Alere Inc.

Major players operating in the global cardiac marker testing devices market are also focused on launching new products to expand their product portfolio. For instance, in September 2019, Hangzhou AllTest Biotech CO., LTD launched its Cardiac troponin T (cTnT) rapid test for the detection of the cardiac marker.

Similarly, in November 2016, Abbott received CE marking for its i-STAT Alinity System, a handheld blood testing platform.

Cardiac Marker Testing Devices Market Taxonomy:

By marker type:

• Lactate Dehydrogenase
• Creatine Kinase (CK)
  • CK-MM
  • CK-MB
  • CK-BB
• Myoglobin
• Natriuretic Peptides
• Aspartate Aminotransferase (AST)
• Cardiac Troponin
• C-reactive Proteins
• Others (galectin-3, myeloperoxidase, homocysteine, H-FABP, and ischemia-modified albumin)

By product type:

• Instruments
  • Chemiluminescence
  • Immunofluorescence
  • Immunochromatography
  • ELISA
• Reagents and kits

By application:

• Acute Coronary Syndrome (ACS)
• Myocardial Infraction (MI)
• Cardiac Heart Failure
• Others

By testing type:

• Laboratory testing
• Pont-of-care testing

By end user:

• Hospitals
• Diagnostic Laboratory
• Home care setting